Phase 3 Parkinson's Disease Trial, Completed

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are male or female and at least 30 years old.
• You have been diagnosed with symptomatic neurogenic orthostatic hypotension (a condition where your blood pressure drops significantly when you stand up), confirmed by a tilt-table test showing a meaningful drop in blood pressure within 3 minutes of being tilted upright.
• You experience symptoms that score at least a 4 out of 10 on a specific dizziness/lightheadedness questionnaire at the time of joining the trial.
• If you have Parkinson's disease: you have been diagnosed according to specific recognised medical criteria (UK Parkinson's Disease Society Brain Bank Criteria, 1992).
• If you have Multiple System Atrophy (MSA): you have a diagnosis of possible or probable MSA of either the Parkinsonian or cerebellar subtype, based on recognised medical criteria (Gilman Criteria, 2008).
• If you have Pure Autonomic Failure (PAF): you have documented test results showing impaired autonomic (automatic nervous system) reflexes, including a specific breathing test called the Valsalva manoeuvre, carried out within the past 24 months.
• A blood test taken after sitting quietly for 30 minutes shows your norepinephrine (a chemical in your blood) levels are above a certain threshold.

Who may not be able to join:

• You have a known whole-body illness that affects the automatic nervous system, such as amyloidosis or certain immune system disorders.
• You have had a bad reaction or intolerance to a certain class of medicines called NRIs or SNRIs (types of antidepressants that affect brain chemicals).
• You are currently taking blood pressure-lowering medication for high blood pressure that is unrelated to your nervous system condition.
• You have taken certain strong medicines that affect how your body processes drugs (called strong CYP1A2 inhibitors or inducers) within roughly the past week or longer (confirm with trial site).
• You have recently changed the dose, type, or frequency of any medication you take for low blood pressure within the 7 days before your first visit, or you have not yet finished tapering off specific medicines (midodrine or droxidopa) at least 7 days before that visit.
• You have had a known or suspected problem with alcohol or substance misuse within the past 12 months.
• You have an unstable heart condition, or you have had a major heart or neurological event (such as a stroke or heart attack) in the past 6 months.
• You have taken a type of medicine called a monoamine oxidase inhibitor (MAO-I) within the past 14 days.
• You have untreated closed-angle glaucoma, or treated closed-angle glaucoma that an eye specialist considers a risk concern.
• You have a significant uncontrolled irregular heartbeat.
• You score 23 or below on a standard memory and thinking assessment called the Montreal Cognitive Assessment (MoCA).
• You have had a heart attack in the past 6 months, or you currently have unstable chest pain (unstable angina).
• You have moderate to severe heart failure (classified as New York Heart Association Class 3 or 4).
• You have significantly abnormal blood test results related to liver function, kidney function, or other values that could affect your safety in the trial (confirm specific thresholds with trial site).
• You have a history of suicidal thoughts or behaviour, as assessed using a standard clinical scale — the trial team will assess this carefully before deciding on eligibility.

Important: Always verify eligibility with the trial site directly before applying.